by Nicco E, Lejon V, Mwamba Miaka E, Mumba D, Mpanya A, Kambo C, Ngolo D, Mutombo W, Hugonnet S, Rembry S, Tipple C, Da Luz RI, Snijders R, Vander Kelen C, Rogé S, Van Reet N, Tarral A, Verlé P, Hasker E. Open Research Europe 2025; 5:23. doi: 110.12688/openreseurope.19077.1.
Summary: The authors of this manuscript outline the background, objectives, and methods of the STROGHAT study, which aims to evaluate whether treatment of parasitologically negative gHAT seropositive participants with acoziborole could lead to elimination of T.b. gambiense from its human reservoir. This one-arm epidemiological study, with a nested phase IIIb, one-arm, open label, non-randomized, multicentre clinical trial will be implemented over four years in the endemic region of the Equateur North, in the Democratic Republic of Congo. For the first three years, parasitologically negative gHAT seropositive subjects will be treated with acoziborole, while parasitologically confirmed cases will receive standard of care. In year four, standard procedures will resume, and a prevalence survey will assess whether interruption of transmission has been achieved.
